source
- FDA advisory panel reviews Replimune's experimental melanoma therapy RP1STAT is live-blogging an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting that convened on Thursday to examine Replimune's engineered viral immunotherapy RP1 for melanoma. The p…
- EFPIA urges EU lawmakers to further cut clinical trial approval timelines under Biotech ActThe European Federation of Pharmaceutical Industries and Associations (EFPIA) has asked EU legislators to go beyond the modest reductions in clinical trial approval times that are currently being c…